Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12

Journal of Molecular Biology

Volumn 410, Issue 5, 2011, Pages 798-810

  Marradi, Marco ^a,b   Di Gianvincenzo, Paolo ^a   Enríquez Navas, Pedro M ^a   Martínez Ávila, Olga M ^a   Chiodo, Fabrizio ^a   Yuste, Eloísa ^c   Angulo, Jesús ^d   Penadés, Soledad ^a,b  

^a CIC BIOMAGUNE   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

Author keywords

2G12 gp120 inhibition; high mannose type oligosaccharides; multivalent gold glyconanoparticles; NMR spectroscopy; surface plasmon resonance

Indexed keywords

GLYCOPROTEIN GP 120; GOLD NANOPARTICLE; MANNOSE OLIGOSACCHARIDE; MONOCLONAL ANTIBODY 2G12; SELF ASSEMBLED MONOLAYER;

ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SATURATION TRANSFER DIFFERENCE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SURFACE PLASMON RESONANCE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; REPLICATION COMPETENT VIRUSES;

EID: 79960351592     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.03.042     Document Type: Article

References (56)

1. De Clercq E. Antiretroviral drugs Curr. Opin. Pharmacol. 10 2010 507 515
2. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission Nature 464 2010 217 223
3. Balzarini J.; and Van Damme L. Microbicide drug candidates to prevent HIV infection Lancet 369 2007 787 797 (Pubitemid 46335821)
4. Barouch D.H. Challenges in the development of an HIV-1 vaccine Nature 455 2008 613 619
5. Mizuochi T.; Spellman M.W.; Larkin M.; Solomon J.; Basa L.J.; and Feizi T. Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gpl20 produced in Chinese-hamster ovary cells Biochem. J. 254 1988 599 603
6. Reitter J.N.; Means R.E.; and Desrosiers R.C. A role of carbohydrates in immune evasion in AIDS Nat. Med. 4 1998 679 684 (Pubitemid 28274667)
7. Wyatt R.; Kwong P.D.; Desjardins E.; Sweet R.W.; Robinson J.; Hendrickson W.A.; and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein Nature 393 1998 705 711 (Pubitemid 28289663)
8. Wei X.; Decker J.M.; Wang S.; Hui H.; Kappes J.C.; and Wu X. Antibody neutralization and escape by HIV-1 Nature 422 2003 307 312 (Pubitemid 36378357)
9. Trkola A.; Purtscher M.; Muster T.; Ballaun C.; Buchacher A.; and Sullivan N. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J. Virol. 70 1996 1100 1108 (Pubitemid 26029030)
10. Scanlan C.N.; Pantophlet R.; Wormald M.R.; Ollmann Saphire E.; Stanfield R.; and Wilson I.A. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 → 2 mannose residues on the outer face of gp120 J. Virol. 76 2002 7306 7321
11. Calarese D.A.; Scanlan C.N.; Zwick M.B.; Deechongkit S.; Mimura Y.; and Kunert R. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition Science 300 2003 2065 2071 (Pubitemid 36760127)
12. Wang L.X. Carbohydrate-based vaccines against HIV/AIDS A.A. Klyosov, Z.J. Witczak, D. Platt, Carbohydrate Drug Design 2006 ACS Symposium Series, No. 932 Washington, DC, USA 133 160
13. Pashov A.; Perry M.; Dyar M.; Chow M.; and Kieber-Emmons T. Defining carbohydrate antigens as HIV vaccine candidates Curr. Pharm. Des. 13 2007 185 201 (Pubitemid 46085292)
14. Doores K.J.; Bonomelli C.; Harveyc D.J.; Vasiljevicc S.; Dwek R.A.; and Burton D.R. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens Proc. Natl Acad. Sci. USA 107 2010 13800 13805
15. Bryan M.C.; Fazio F.; Lee H.K.; Huang C.Y.; Chang A.; and Best M.D. Covalent display of oligosaccharide arrays in microtiter plates J. Am. Chem. Soc. 126 2004 8640 8641 (Pubitemid 38955714)
16. Adams E.W.; Ratner D.M.; Bokesch H.R.; McMahon J.B.; O'Keefe B.R.; and Seeberger P.H. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology: glycan-dependent gp120/protein interactions Chem. Biol. 11 2004 875 881 (Pubitemid 38836903)
17. Blixt O.; Head S.; Mondala T.; Scanlan C.; Huflejt M.E.; and Alvarez R. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins Proc. Natl Acad. Sci. USA 101 2004 17033 17038 (Pubitemid 39627769)
18. Calarese D.A.; Lee H.K.; Huang C.Y.; Best M.D.; Astronomo R.D.; and Stanfield R.L. Dissection of the carbohydrate specificity of broadly neutralizing anti-HIV-1 antibody 2G12 Proc. Natl Acad. Sci. USA 102 2005 13372 13377 (Pubitemid 41420854)
19. Liang P.H.; Wang S.K.; and Wong C.H. Quantitative analysis of carbohydrate-protein interactions using glycan microarrays: determination of surface and solution dissociation constants J. Am. Chem. Soc. 129 2007 11177 11184
20. Wang L.X.; Ni J.; Singh S.; and Li H. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design Chem. Biol. 11 2004 127 134 (Pubitemid 38203997)
21. Li H.; and Wang L.X. Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12 Org. Biomol. Chem. 2 2004 483 488
22. Dudkin V.Y.; Orlova M.; Geng X.; Mandal M.; Olson W.C.; and Danishefsky S.J. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency J. Am. Chem. Soc. 126 2004 9560 9562 (Pubitemid 39031041)
23. Krauss I.J.; Joyce J.G.; Finnefrock A.C.; Song H.C.; Dudkin V.Y.; and Geng X. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody J. Am. Chem. Soc. 129 2007 11042 11044 (Pubitemid 47435706)
24. Wang J.; Li H.; Zou G.; and Wang L.X. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study Org. Biomol. Chem. 5 2007 1529 1540 (Pubitemid 46959421)
25. Wang S.K.; Liang P.H.; Astronomo R.D.; Hsu T.L.; Hsieh S.L.; Burton D.R.; and Wong C.H. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN Proc. Natl Acad. Sci. USA 105 2008 3690 3695 (Pubitemid 351723459)
26. Lee H.K.; Scanlan C.N.; Huang C.Y.; Chang A.Y.; Calarese D.A.; and Dwek R.A. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody Angew. Chem. Int. Ed. 43 2004 1000 1003 (Pubitemid 39258001)
27. 197 glycoconjugates Glycoconjugate J. 27 2010 501 513
28. Astronomo R.D.; Kaltgrad E.; Udit A.K.; Wang S.K.; Doores K.J.; and Huang C.Y. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds Chem. Biol. 17 2010 357 370
29. Ni J.; Song H.; Wang Y.; Stamatos N.M.; and Wang L.X. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates Bioconjugate Chem. 17 2006 493 500
30. Astronomo R.D.; Lee H.K.; Scanlan C.N.; Pantophlet R.; Huang C.Y.; and Wilson I.A. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 J. Virol. 82 2008 6359 6368 (Pubitemid 351875114)
31. Joyce J.G.; Krauss I.J.; Song H.C.; Opalka D.W.; Grimm K.M.; and Nahas D.D. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions Proc. Natl Acad. Sci. USA 105 2008 15684 15689
32. Luallen R.J.; Lin J.; Fu H.; Cai K.K.; Agrawal C.; and Mboudjeka I. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies J. Virol. 82 2008 6447 6457 (Pubitemid 351875122)
33. Dunlop D.C.; Bonomelli C.; Mansab F.; Vasiljevic S.; Doores K.J.; and Wormald M.R. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans Glycobiology 20 2010 812 823
34. Agrawal-Gamse C.; Luallen R.J.; Liu B.; Fu H.; Lee F.H.; Geng Y.; and Doms R.W. Yeast-elicited cross-reactive antibodies to HIV env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans J. Virol. 85 2011 470 480
35. de La Fuente J.M.; Barrientos A.G.; Rojas T.C.; Rojo J.; Cañada J.; Fernández A.; and Penadés S. Gold glyconanoparticles as water-soluble polyvalent models to study carbohydrate interactions Angew. Chem. Int. Ed. Engl. 40 2001 2257 2261
36. Barrientos A.G.; de la Fuente J.M.; Rojas T.C.; Fernández A.; and Penadés S. Gold glyconanoparticles: synthetic polyvalent ligands mimicking glycocalyx-like surfaces as tools for glycobiological studies Chem. Eur. J. 9 2003 1909 1921
37. Marradi M.; Martín-Lomas M.; and Penadés S. Glyconanoparticles: polyvalent tools to study carbohydrate-based interactions Adv. Carbohydr. Chem. Biochem. 64 2010 211 290
38. Rojo J.; Diaz V.; de la Fuente J.M.; Segura I.; Barrientos A.G.; and Riese H.H. Gold glyconanoparticles as new tools in antiadhesive therapy ChemBioChem 5 2004 291 297 (Pubitemid 39257122)
39. Martínez-Ávila O.; Hijazi K.; Marradi M.; Clavel C.; Campion C.; Kelly C.; and Penadés S. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN Chem. Eur. J. 15 2009 9874 9888
40. Geijtenbeek T.B.H.; Kwon D.S.; Torensma R.; van Vliet S.J.; van Duijnhoven G.C.F.; and Middel J. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells Cell 100 2000 587 597
41. Martínez-Ávila O.; Bedoya L.M.; Marradi M.; Clavel C.; Alcamí J.; and Penadés S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells ChemBioChem 10 2009 1806 1809
42. Sattin S.; Daghetti A.; Thépaut M.; Berzi A.; Sánchez- Navarro M.; and Tabarani G. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation Chem. Biol. 5 2010 301 312
43. Feinberg H.; Mitchell D.A.; Drickamer K.; and Weis W.I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR Science 294 2001 2163 2166 (Pubitemid 33150672)
44. He L.; Musick M.D.; Nicewarner S.R.; Salinas F.G.; Benkovic S.J.; Natan M.J.; and Keating C.D. Colloidal Au-enhanced surface plasmon resonance for ultrasensitive detection of DNA hybridization J. Am. Chem. Soc. 122 2000 9071 9077
45. Kong L.; Sheppard N.C.; Stewart-Jones G.B.E.; Robson C.L.; Chen H.; and Xu X. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity J. Mol. Biol. 403 2010 131 147
46. Mayer M.; and Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectra Angew. Chem. Int. Ed. 38 1999 1784 1788 (Pubitemid 29290947)
47. Enríquez-Navas P.M.; Marradi M.; Padro D.; Angulo J.; and Penadés S. A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands Chem. Eur. J. 17 2011 1369 1707
48. Angulo J.; Enríquez-Navas P.M.; and Nieto P.M. Ligand-receptor binding affinities from saturation transfer difference (STD) NMR spectroscopy: the binding isotherm of STD initial growth rates Chem. Eur. J. 16 2010 7803 7812
49. Mayer M.; and Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor J. Am. Chem. Soc. 123 2001 6108 6117 (Pubitemid 32888480)
50. Benie A.J.; Moser R.; Bäuml E.; Blaas D.; and Peters T. Virus-ligand interactions: identification and characterization of ligand binding by NMR spectroscopy J. Am. Chem. Soc. 125 2003 14 15 (Pubitemid 36068625)
51. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
52. Derdeyn C.A.; Decker J.M.; Sfakianos J.N.; Wu X.; O'Brien W.A.; and Ratner L. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 J. Virol. 74 2000 8358 8367 (Pubitemid 30666686)
53. Platt E.J.; Wehrly K.; Kuhmann S.E.; Chesebro B.; and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 72 1998 2855 2864 (Pubitemid 28175522)
54. Wei X.; Decker J.M.; Liu H.; Zhang Z.; Arani R.B.; and Kilby J.M. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 2002 1896 1905 (Pubitemid 34535213)
55. Fenyo E.M.; Heath A.; Dispinseri S.; Holmes H.; Lusso P.; and Zolla-Pazner S. International network for comparison of HIV neutralization assays: the NeutNet report PLoS One 4 2009 e4505
56. Garcia-Perez J.; Sanchez-Palomino S.; Perez-Olmeda M.; Fernandez B.; and Alcami J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1 J. Med. Virol. 79 2007 127 137 (Pubitemid 46048500)